Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Ballard

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Psychopharmacology|March 21, 2008
Cognitive performance in neurokinin 3 receptor knockout miceR E Nordquist, M Delenclos, T M Ballard, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 26, 2011
PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disordersS Saenger, C Goeldner, J R Frey, et al.
British Journal of Pharmacology|November 3, 2010
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptorsP Malherbe, F Knoflach, M C Hernandez, et al.
Neuropharmacology|July 11, 2001
Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological functionG A Higgins, A J Grottick, T M Ballard, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Psychopharmacology|March 21, 2008
Cognitive performance in neurokinin 3 receptor knockout miceR E Nordquist, M Delenclos, T M Ballard, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 26, 2011
PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disordersS Saenger, C Goeldner, J R Frey, et al.
British Journal of Pharmacology|November 3, 2010
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptorsP Malherbe, F Knoflach, M C Hernandez, et al.
Neuropharmacology|July 11, 2001
Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological functionG A Higgins, A J Grottick, T M Ballard, et al.
Pageof 2